Effectiveness analysis of montelukast sodium combined with budesonide formoterol in treating bronchial asthma in children
HE Lu
NIU Liaoze
CHENG Jing
WANG Caihong
Abstract：Objective To evaluate the effectiveness of montelukast sodium combined with budesonide for-moterol in the treatment of bronchial asthma in children.Methods A total of 120 children diagnosed with bronchial asthma treated at Taiyuan Maternal and Child Health Hospital between January 2022 and December 2023 were select-ed and allocated into two groups via a random number table.The budesonide formoterol group(n=60)was treated with budesonide and formoterol fumarate powder for inhalation(Ⅰ).The montelukast sodium group(n=60)was provided with a combined therapy of montelukast sodium chewable tablets in addition to the identical inhalation treatment.The effica-cy of the montelukast sodium group and the budesonide formoterol group was evaluated by monitoring inflammatory fac-tors(interleukin-6(IL-6),interleukin-10(IL-10),and tumor necrosis factor α(TNF-α))and pulmonary function indicators(first-second forced expiratory volume(FEV1),forced expiratory vital capacity(FVC),peak expiratory flow rate(PEF))before and after treatment.The improvement of cough symptoms was recorded,and the medication safety was evaluat-ed.Results The montelukast sodium group demonstrated a higher overall response rate of 93.33％(56/60)compared to 78.33％(47/60)in the budesonide formoterol group,with a statistically significant difference(x2=5.551,P＜0.05).After treat-ment,the montelukast sodium group exhibited significantly lower daily and nocturnal cough scores(daily:(0.61±0.24)points vs(1.32±0.54)points;nocturnal:(0.74±0.17)points vs(1.22±0.26)points).Meanwhile,pulmonary function parameters including FEV1,FVC,PEF,FEV1/FVC and the anti-inflammatory cytokine IL-10 were all higher in the montelukast sodium group than those in the budesonide formoterol group(FEV1:(2.33±0.64)L vs(1.72±0.54)L;FVC:(2.86±0.47)L vs(2.49±0.36)L;PEF:(4.54±0.69)L/s vs(4.26±0.64)L/s;FEV1/FVC:(0.81±0.19)vs(0.69±0.16);IL-10:(38.34±4.22)ng/L vs(27.56±3.31)ng/L).The levels of the inflammatory markers IL-6 and TNF-α were lower in the montelukast sodium group(IL-6:(20.53±2.43)ng/L vs(25.46±3.37)ng/L;TNF-α:(9.24±3.34)ng/L vs(16.86±5.21)ng/L),and all the above differences were statistically significant(t=5.643,4.841,3.305,3.742,15.569,9.191,9.537,all P＜0.05).No significant difference was observed in the total incidence of ad-verse reactions between the montelukast sodium group(13.33％,8/60)and the budesonide formoterol group(6.67％,4/60)(x2=1.481,P=0.223).Conclusion The combination therapy was associated with attenuated cough symptoms and mitigated inflammation in pediatric asthma patients.It also played a beneficial role in lung function recovery and demonstrated a high level of safety.
Keywords：budesonide formoterolmontelukast sodiumbronchial asthmachildreninflammatory factorslung function
Publication Date：2026-01-25
Online Publishing Date：2026-03-03(First online date of this platform, not the publication date of the document)
Pages：5( 97-101 )